Study of Endometrial Immune and Microbiological Modifications in Cases of Recurrent Implantation Failure and/or Recurrent Pregnancy Loss

Starting soon · Not applicable

Conditions studied: Recurrent Implantation Failure, Recurrent Pregnancy Loss, Infertility, Female, Endometrial Diseases, Endometritis, Endometriosis, Adenomyosis

In brief

The IMERR study aims to improve understanding of certain causes of infertility related to recurrent implantation failure (RIF) and/or recurrent pregnancy loss (RPL), conditions that affect many women undergoing assisted reproductive technology (ART). Despite medical advances, some patients repeatedly fail to achieve pregnancy, or experience repeated miscarriages. These situations may be linked to subtle immune or microbial disturbances in the uterus. This study seeks to identify immune and microbiological profiles in the endometrium during the implantation window-a crucial period when the embryo attaches to the uterine wall. We will compare women who have experienced RIF and/or RPL with women who have had no such history. Blood and uterine samples will be analyzed to investigate whether certain immune or microbial features are associated with these reproductive failures. The ultimate goal is to uncover predictive factors that may explain why some women experience implantation failure or pregnancy loss, and to lay the foundation for future personalized treatments to improve reproductive outcomes.

Key facts

Study ID

NCT07265505

Run by

Assistance Publique - Hôpitaux de Paris

People needed

100

Starts

2026-04-01

Expected to finish

2031-04-01

Last updated by the study team

2026-02-05

Who can join

Age: 18 and older, up to 35. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female aged ≥18 and <36 years
• Undergoing assisted reproductive technology (ART) in a fertility center
• Covered by the French national health insurance system
• Belonging to one of two groups:
• Study group: history of recurrent implantation failure (RIF) and/or recurrent pregnancy loss (RPL)
• Control group: no history of RIF or RPL

You may not qualify if…

• Pregnant at inclusion
• Refusal to provide written informed consent
• Antibiotic use within one month prior to endometrial biopsy Positive serology for hepatitis B, hepatitis C or HIV
• Uterine anatomical abnormalities (e.g., polyps, cavity-distorting fibroids, untreated hydrosalpinx)
• Known chromosomal abnormality in either partner
• Known autoimmune disease, thrombophilia, or antiphospholipid antibody syndrome
• Persons under legal protection (e.g., guardianship, curatorship)

Where it is running

• Service de Gynécologie Obstétrique II et Médecine de la Reproduction - Cochin Hospital — Paris, IDF, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.